# GSK plc (GSK.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Pharmaceuticals. Price 1822p, market value 73.0 billionp.

## Valuation
- **P/E (trailing): 15.4×** (5-yr avg 1254.4×, 3-yr avg 1561.8×). GSK plc trades at 15.4× trailing earnings, well below its own five-year average of 1254.4×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.08**. A PEG of 0.08 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 7.8×**. Enterprise value is 7.8× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 7.7%** (5-yr avg 0.1%). Free cash flow equals 7.7% of the market value, above its five-year average of 0.1%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 6.5%**. The inverse of the P/E: 6.5% of the price is earned each year.

## Profitability
- **Gross margin: 72.8%**. GSK plc keeps 72.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 18.3%**. 18.3% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 17.5%**. 17.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 34.9%**. 34.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 17.5%**. Return on all capital, debt included, is 17.5%: comfortably above what that capital costs.
- **Return on assets: 7.9%**. Each dollar of assets produces 7.9% of profit.

## Growth
- **Revenue growth (1 yr): 4.1%** (3-yr 3.7%/yr, 5-yr -0.9%/yr). Revenue grew 4.1% over the last year, against -0.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 123.6%** (3-yr -27.6%/yr, 5-yr -0.5%/yr). Earnings per share rose 123.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 5.0%/yr**. Free cash flow has compounded at 5.0% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.08**. Debt is 1.08 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 1.3×**. It would take 1.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 8.7×**. Operating profit covers interest 8.7× over, a safe margin.
- **Current ratio: 0.82** (quick 0.54). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 2.20**. A Z-score of 2.20 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 9/9**. 9 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 3.68%** (1p per share, trailing). GSK plc yields 3.68%, an income-level yield.
- **Payout ratio: 45%** (48% of free cash flow). 45% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 2**. 2 straight years of increases.
- **Dividend growth (5 yr): -8.5%/yr** (1-yr 4.9%). The dividend has not grown over five years.
- **Shareholder yield: 5.0%**. Dividends plus net buybacks return 5.0% of the market value a year.

## Analyst view
- **Analyst consensus: hold** (20 analysts). 20 analysts cover GSK plc; the consensus is hold, with an average price target of 2169p (+19% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 24.4%** (YTD 0.6%, 3-mo -4.1%). The shares are up 24.4% over twelve months including dividends.
- **From 52-week high: -20.2%** (25.2% above the low). Trading 20% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.06** (volatility 25%). Beta of 1.06 against the FTSE All-Share: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GSK.L · Page: https://foliofundamentals.com/stocks/gsk.l

Not investment advice.